Mitsubishi UFJ Asset Management Co. Ltd. Buys New Stake in DaVita Inc. $DVA

Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in DaVita Inc. (NYSE:DVA) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 39,712 shares of the company’s stock, valued at approximately $8,835,000.

A number of other large investors have also made changes to their positions in the business. Beverly Hills Private Wealth LLC purchased a new stake in shares of DaVita during the 2nd quarter valued at $263,000. Plato Investment Management Ltd acquired a new position in DaVita during the 2nd quarter valued at about $87,000. Global Retirement Partners LLC purchased a new stake in DaVita in the second quarter valued at about $414,000. Fielder Capital Group LLC acquired a new stake in DaVita in the second quarter worth about $317,000. Finally, Bank of New York Mellon Corp acquired a new stake in DaVita in the second quarter worth about $101,127,000. 90.12% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have recently issued reports on DVA. TD Cowen upgraded shares of DaVita from a “hold” rating to a “buy” rating and upped their price objective for the company from $201.00 to $220.00 in a report on Friday, August 7th. Truist Financial lowered their target price on shares of DaVita from $250.00 to $215.00 and set a “hold” rating for the company in a research note on Friday, August 7th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $265.00 target price on shares of DaVita in a research report on Wednesday, August 5th. Weiss Ratings raised shares of DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 5th. Finally, Oppenheimer set a $220.00 price objective on shares of DaVita in a research note on Friday, August 7th. Four equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $221.75.

Insider Activity

In other news, insider Kathleen Alyce Waters sold 15,405 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $208.40, for a total value of $3,210,402.00. Following the completion of the transaction, the insider owned 109,194 shares of the company’s stock, valued at $22,756,029.60. The trade was a 12.36% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 1.90% of the stock is currently owned by company insiders.

DaVita Stock Down 1.0%

Shares of NYSE:DVA opened at $175.54 on Friday. DaVita Inc. has a 52-week low of $101.00 and a 52-week high of $247.49. The stock has a market cap of $11.20 billion, a price-to-earnings ratio of 14.36, a PEG ratio of 0.59 and a beta of 0.88. The business has a 50-day moving average price of $215.64 and a 200-day moving average price of $181.58.

DaVita (NYSE:DVA) last issued its earnings results on Tuesday, August 4th. The company reported $4.02 EPS for the quarter, beating analysts’ consensus estimates of $3.88 by $0.14. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%.The firm had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.50 billion. During the same quarter in the prior year, the firm earned $2.95 earnings per share. DaVita’s revenue for the quarter was up 5.2% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, equities analysts anticipate that DaVita Inc. will post 14.57 EPS for the current fiscal year.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.